Allergic Rhinitis
Conditions
Interventions
This project is characterized as a randomized, placebo-controlled clinical trial with a sample number (n) = 60 patients with allergic rhinitis, regardless of gender and age range between 18 and 59 yea
E02.594
Sponsors
Pontifícia Universidade Católica do Paraná
Marco Aurelio Fornazieri
Eligibility
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Patients between 18 and 59 years old; Confirmed diagnosis of allergic rhinitis by medical history and positive specific IgE test
Exclusion criteria
Exclusion criteria: Not completing the follow-up period; History of previous nasal surgery; History of antibiotic use for acute illnesses or purulent nasal secretions in the last 4 weeks prior to the start of the research; Ongoing/active upper airway infection (URTI); Inability to complete the test; Asthma; Anosmia; Nasofibroscopy with polyps; Incomplete high school; History of traumatic brain injury; Women with a UPSIT score less than or equal to 18; Men with a UPSIT score less than or equal to 16; Pregnant and breastfeeding women; Use of antihistamines in the last 30 days; Use of corticosteroids in the last 30 days; Use of vasoconstrictor in the last 30 days; Patients with psychiatric or neurological disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the effectiveness of using photobiomodulation therapy in patients with allergic rhinitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess olfactory function before treatment, 1 month after starting treatment using the olfactory test (UPSIT);Assess nasal obstruction using Peak Nasal Inspiratory Flow (PNIF) 1 month after starting treatment.;Assess the symptoms experienced in the last week using the Rhinitis Control Assessment Test (RCAT) 1 month after starting treatment.;Assess Nasal Obstruction Symptoms using the Scale (NOSE) 1 month after starting treatment. | — |
Countries
Brazil
Contacts
Public ContactMarco Fornazieri
Clinica Olfact
Outcome results
None listed